CAMBRIDGE, Mass.–(BUSINESS WIRE)–bluebird
bio, Inc. (Nasdaq: BLUE) today announced that the Company will host
an Analyst Day, Thursday, May 9, at 8:30 am ET at The Maxwell Hotel NYC,
New York, NY.
In addition, members of the management team will present at the Bank of
America Merrill Lynch Health Care Conference 2019, Tuesday, May 14, at
3:00 pm PT at the Encore Hotel, Las Vegas, NV.
To access the live webcasts of bluebird bio’s presentations, please
visit the “Events & Presentations” page within the Investors & Media
section of the bluebird bio website at http://investor.bluebirdbio.com.
Replays of the webcasts will be available on the bluebird bio website
for 90 days following the events.
About bluebird bio, Inc.
bluebird bio is pioneering gene therapy with purpose. From our
Cambridge, Mass., headquarters, we’re developing gene therapies for
severe genetic diseases and cancer, with the goal that people facing
potentially fatal conditions with limited treatment options can live
their lives fully. Beyond our labs, we’re working to positively disrupt
the healthcare system to create access, transparency and education so
that gene therapy can become available to all those who can benefit.
bluebird bio is a human company powered by human stories. We’re putting
our care and expertise to work across a spectrum of disorders by
researching cerebral adrenoleukodystrophy, sickle cell disease,
transfusion-dependent β-thalassemia and multiple myeloma using three
gene therapy technologies: gene addition, cell therapy and
(megaTAL-enabled) gene editing.
bluebird bio has additional nests in Seattle, Wash.; Durham, N.C.; and
Zug, Switzerland. For more information, visit bluebirdbio.com.
This release contains “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995, including
statements regarding the advancement of, and anticipated development and
commercialization plans for, the Company’s product candidates. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, the risks that the preliminary positive efficacy and safety results
from our prior and ongoing clinical trials of our product candidates
will not continue or be repeated in our ongoing or planned clinical
trials; risks that the current or planned clinical trials of our product
candidates will be insufficient to support future regulatory submissions
or to support marketing approval in the U.S. and EU; and the risk that
our product candidates will not be successfully developed, approved or
commercialized. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in our most recent Form 10-Q as well as
discussions of potential risks, uncertainties and other important
factors in our subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date of
the release, and bluebird bio undertakes no duty to update this
information unless required by law.